The accountability layer for clinical AI

AIGuardian monitors the whole imaging chain — the scanners, the PACS and RIS interfaces, every AI you run, and the read itself. Not just whether the model is right, but whether the chain around it is still working.

300K+Cases monitored in live clinical routine
3 yrsUnbroken production deployment
A doctor talking with a patient across a desk in a consulting room.

Your imaging chain, monitored end to end

Studies arrive from the scanners into PACS and RIS. From there they are sent out to every AI you run, and every AI result returns to PACS — which is where the radiologist reads it. We watch each link and each interface between them, and we keep a live performance trace on every tool. When one leaves its agreed bounds, it lights up here.

Acquisition Routing hub AI tools Reading Output DICOM DICOM store DICOM SR / GSPS HL7 worklist HL7 / report CT X-ray MRI PACSRIS Fracture AI Chest AI Stroke AI Radiologist Report AIGuardian · one independent layer across the whole chain Inputs Routing & protocols Models Oversight Output Live performance trace · Chest AI · agreed bounds shaded All tools within agreed bounds Chest AI · outside bounds · alert raised, vendor notified

Scroll the diagram sideways to see the whole chain.

Vendor agnostic — every AI, whoever built it PACS and RIS agnostic — no change to how radiologists read Cloud or on-premises — imaging can stay behind your firewall

The concept

A correct model on a broken interface is a broken deployment

Most monitoring in this market watches the algorithm. That is the smaller half of the problem. Between the scanner and the signed report there are half a dozen handovers, each one carried by a protocol that can fail without raising an error anywhere.

Studies that never arrive

A modality worklist entry, a changed AE title, a study description that no longer matches a routing rule. The AI is running perfectly and simply never sees the case.

Results that never land

A structured report or overlay comes back but is filed against the wrong series, lands in a tab nobody opens, or is silently rejected by the archive. The AI did its job. Nobody saw it.

Handovers that quietly degrade

Priors that stop being fetched, headers that lose a field after a PACS upgrade, results that arrive after the study has already been read. Everything reports success. The clinical value is gone.

This is why we monitor the chain rather than the model. If the AI is right and the interface is wrong, the patient gets the same outcome as if the AI were wrong — and nobody in the department has the evidence to tell the two apart.

A chest radiograph on a viewing screen.

The chain, not the model

Every link between the scanner and the report can fail on its own

A model can be performing exactly as validated while the study never reaches it, the result never lands back in PACS, or the protocol it was tuned for has quietly been changed on the scanner. We watch the links, not only the prediction.

Every study that reaches a tool, and every result that comes back, is accounted for.

Where it breaks

Clinical AI rarely fails as a wrong answer

It fails somewhere along the chain, quietly, in a way that produces no error message. Pick a point.

What goes wrong

The environment moves under the tool

A scanner is replaced. A protocol is adjusted. A service starts seeing a different population. The model has not changed, but what it is being asked to judge has.

What you get

Change is attributed, not guessed at

You are told what shifted in the inputs and when, so a drop in performance is traced to its cause instead of being blamed on the algorithm or on the radiologists.

Controlled deployment

The same measurements that prove a tool works are what get it into routine use faster

Most of the time between signing for an imaging AI and actually relying on it is spent arguing about whether it works. Measuring the deployment against your own data replaces the argument with evidence — what the tool is really reporting, how that should reach the people reading it, and where the thresholds belong.

Grounded in your data

Decisions from your department

Every judgement about the deployment is made against measurements from the population and the systems you actually run, not the validation set the tool was sold on.

Controlled change

Thresholds move in steps

Each adjustment is measured before and after, against live traffic. A change that does not help is visible immediately, and it is reversible.

Faster to routine use

Evidence shortens the argument

Departments reach the point of trusting a tool sooner, and can say why. Adoption stops depending on whoever argues hardest in the meeting.

No extra work

The record writes itself

The measurements that guide the deployment are the same ones a board, an auditor or a notified body will ask for later. Nothing is assembled twice.

Who it is for

Peace of mind for everyone who now depends on this AI

Radiology is where clinical AI actually landed. Of the 1,524 AI-enabled devices the FDA has authorised, 1,164 are radiology devices — 76% — and the people carrying the risk are no longer only the hospital.

Health systems and hospitals

You signed for it

Deployment is nearly universal and confidence is not. You need a standing answer to whether each tool is still working, and a record you can hand to a board or a regulator.

In a 2024 survey of 43 US health systems, imaging was the most widely deployed clinical AI use case, with 90% reporting at least partial deployment — while the same study found reported success with diagnostic use cases was limited.

Radiologists and reading groups

You carry the read

You are asked to rely on a tool you cannot audit. Independent measurement tells you where it is strong, where it is not, and when something has changed.

In the European Society of Radiology's 2024 member survey, 274 of 572 respondents (48%) said they currently use AI, and a further 25% planned to.

AI manufacturers

You need field evidence

Multi-site, real-world performance data you cannot collect from outside a customer's firewall — for post-market surveillance, for renewals, and for a change control plan you can actually execute.

The FDA authorised 92 AI-enabled devices in the first quarter of 2026 alone, 75% of them in radiology.

Imaging OEMs and platforms

You ship AI inside the box

When AI arrives embedded in a scanner or a PACS, the obligation to show it still performs travels with it. An independent layer gives your customers that without you grading your own work.

The five largest holders of radiology AI authorisations are equipment manufacturers — GE HealthCare, Siemens Healthineers, Philips, Canon and United Imaging — ahead of every AI-native vendor.

Sources: FDA AI-Enabled Medical Device List, authorisations through March 2026. Poon et al., JAMIA 2025, cross-sectional survey of 43 US health systems (Scottsdale Institute members, fielded autumn 2024). Zanardo et al., Insights into Imaging 2024, EuroAIM/EuSoMII survey of ESR members — 572 responses from 28,000 members contacted, so respondents are likely to be more AI-engaged than the profession as a whole. Device counts change with each FDA update.

A clinician examining a patient in a treatment room.

The people carrying the risk

Behind every alert there is someone who has to act on it

The radiologist signing the read, the physicist who validated the tool, the clinical safety officer who signed it off. Each needs a different answer from the same evidence, and each needs it before a problem becomes an incident.

Alerts are written for the person who receives them, not for a dashboard.

Change control

We make a Predetermined Change Control Plan executable

A cleared model is frozen at the version that was approved. The FDA's final PCCP guidance, issued in August 2025, is the way out: a manufacturer can pre-specify what it may change, how it will validate it, and inside what performance bounds — then ship improvements without refiling. The problem is that a plan on paper is not a plan you can run.

Performance bounds

Numeric limits agreed across the many signals we measure, not one headline accuracy figure — measured where the device actually runs.

A validation method

A defensible, repeatable way of establishing what happened in each case, applied identically across every site we monitor.

Working monitoring

Not an intention to monitor. A pipeline already measuring cases inside customer sites, in production, today.

A stop rule that fires

An agreed threshold at which an update is rolled back — and a mechanism that will actually detect it and raise the alert.

For the manufacturer this turns a frozen model into one that can improve under supervision. For the hospital it means the version running this morning is still the version that was assessed. Both sides get the same thing from it: the ability to change something without losing control of it.

The obligation

Approval covers the moment. The duty covers the years after.

Every framework governing clinical AI has arrived at the same requirement: know how the tool performs where it is actually used, and be able to show it.

  • In forceEU Medical Device Regulation

    Post-market surveillance and real-world clinical follow-up, for the life of the device.

  • Aug 2025FDA PCCP final guidance

    Marketing submission recommendations for a Predetermined Change Control Plan for AI-enabled device software functions. Pre-authorised change, against declared bounds and real monitoring.

  • May 2026ACR-SIIM practice parameter

    The first professional standard for imaging AI: selection, pre-deployment evaluation, ongoing performance monitoring and stop rules, with facility recognition for sites that implement it.

  • Dec 2027EU AI Act, stand-alone high-risk

    Deferred from August 2026 by the Digital Omnibus, which moved the dates and left the duties untouched.

  • Aug 2028EU AI Act, device-embedded AI

    Where imaging AI sits. Oversight, monitoring of operation, logging and escalation fall on the organisation running the system.

Proof

The contract that nearly was not signed. Then first reader across the network.

A fracture-detection AI in a live urgent-care network was not earning the confidence of the clinicians asked to rely on it, and the contract was close to not being signed. Measuring the deployment against its own data showed what the results actually meant and how they had to be presented to radiologists, and where the thresholds needed to move. The changes were made under control and verified against live data — continuously, over the years since rather than in a single retest.

The situation

Too many positives were not holding up on review. Confidence was low and the contract was close to not being signed.

What we found

The results were not reaching radiologists in a form that reflected what the tool was actually reporting.

What happened

Presentation was corrected, then thresholds were adjusted in controlled steps, each one measured against live data.

Where it ended

The same tool was promoted to first reader for every radiologist and front-line clinician.

Nothing about the algorithm was replaced. A deployment measured against its own data can be improved quickly, in controlled steps, with the evidence for every change.

A quiet hospital corridor outside an imaging department.

This runs where the work happens

Installed beside the PACS, watching live traffic. No change to how radiologists read, and no case leaves the hospital.

Find out what your AI is actually doing

Tell us which tools you run and on which systems. We will show you what the monitoring record would look like for them, with a radiologist in the room.